Literature DB >> 19537717

Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts.

Yonit Kasherman1, Stefan Sturup, Dan Gibson.   

Abstract

Cisplatin is an anticancer drug whose efficacy is limited because tumors develop resistance to the drug. Resistant cells often have elevated levels of cellular glutathione (GSH), believed to be the major cellular target of cisplatin that inactivates the drug by binding to it irreversibly, forming [Pt(SG)(2)] adducts. We show by [(1)H,(15)N] HSQC that the half-life of (15)N labeled cisplatin in whole cell extracts is approximately 75 min, but no Pt-GSH adducts were observed. When the low molecular mass fraction (<3 kDa) of the extracts was incubated with cisplatin, binding to GSH was observed probably due to removal of high molecular mass platinophiles. Two-thirds of the Pt adducts formed in whole cell extracts, had a molecular mass >3 kDa. [Pt(SG)(2)] cannot account for more than 20% of the Pt adducts. The concentration of reduced thiols in the high molecular mass fraction of the extracts is six times higher than in the low molecular mass fraction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19537717     DOI: 10.1021/jm900138u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

1.  The trans influence in the modulation of platinum anticancer agent biology: the effect of nitrite leaving group on aquation, reactions with S-nucleophiles and DNA binding of dinuclear and trinuclear compounds.

Authors:  Eva I Montero; Junyong Zhang; Joseph J Moniodis; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chemistry       Date:  2010-08-09       Impact factor: 5.236

2.  Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Authors:  Dong Lan; Li Wang; Rongquan He; Jie Ma; Yehong Bin; Xiaojv Chi; Gang Chen; Zhengwen Cai
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

3.  Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.

Authors:  Jonathan F Arambula; Jonathan L Sessler; Zahid H Siddik
Journal:  Bioorg Med Chem Lett       Date:  2011-01-26       Impact factor: 2.823

4.  A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents.

Authors:  Amrit Sarmah; Ram Kinkar Roy
Journal:  J Comput Aided Mol Des       Date:  2014-09-03       Impact factor: 3.686

5.  Cisplatin handover between copper transporters: the effect of reducing agents.

Authors:  Angela Galliani; Maurizio Losacco; Alessia Lasorsa; Giovanni Natile; Fabio Arnesano
Journal:  J Biol Inorg Chem       Date:  2014-05-01       Impact factor: 3.358

6.  Reactivity of hexanuclear ruthenium metallaprisms towards nucleotides and a DNA decamer.

Authors:  Lydia E H Paul; Bruno Therrien; Julien Furrer
Journal:  J Biol Inorg Chem       Date:  2014-11-08       Impact factor: 3.358

7.  Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocyanates.

Authors:  Anthony J Di Pasqua; Charles Hong; Mona Y Wu; Erin McCracken; Xiantao Wang; Lixin Mi; Fung-Lung Chung
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

8.  Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy.

Authors:  Helen H W Chen; Macus Tien Kuo
Journal:  Met Based Drugs       Date:  2010-09-14

9.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

Review 10.  The Platin-X series: activation, targeting, and delivery.

Authors:  Uttara Basu; Bhabatosh Banik; Ru Wen; Rakesh K Pathak; Shanta Dhar
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.